Treatment guidelines recommend that patients with CKD and T2D be treated with renin–angiotensin-aldosterone system inhibitors (angiotensin-converting enzyme inhibitors [ACEis] or angiotensin receptor blockers [ARBs]) alongside sodium–glucose cotransporter 2 (SGLT2) inhibitors, and/or glucagon-like peptide-1 (GLP-1) receptor agonists (to achieve adequate glycemic control) [9, 10]. The gene discussed is REN; the disease is type 2 diabetes mellitus.